Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04228445 · ClinicalTrials.gov registry record · Phase 3
3,3'-Dioxo-2,2'-Bisindolylidene-5,5'-Disulfonate Disodium 0.8% Solution as an Aid for Ureteral Patency
A Phase 3 study of Ureter Injury, sponsored by Prove pharm.
- Completed
- Registry status
- Phase 3
- Development phase
- 121
- Enrollment target
- 1
- Study location
NCT04228445 is a Phase 3 study of Ureter Injury that has completed, run by Prove pharm. The registered enrollment target is 121 participants, above the 91-participant average among 5 other Ureter Injury trials with a reported enrollment target (33% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04228445, a Phase 3 study of Ureter Injury, has completed, sponsored by Prove pharm.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 121 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine whether the use of 3,3'-Dioxo-2,2'-Bisindolylidene-5,5'-Disulfonate Disodium 0.8% Solution for injection provides a visualization advantage compared to saline when used as an aid in the determination of ureteral patency
Conditions Studied
Interventions
- DRUG Saline spray
- DRUG 3,3'-Dioxo-2,2'-bisindolylidene-5,5'-disulfonate disodium 0.8%
Study Locations (1)
Nebraska
- Adult and Pediatric Urology - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2020-02-13 |
| Est. Completion | 2021-06-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04228445
The ClinicalTrials.gov registry entry for NCT04228445 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 91-participant average among 5 other Ureter Injury trials with a reported enrollment target (33% higher). The listed sponsor is Prove pharm, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ureter Injury appearing as the primary indexed condition, and to 2 interventions - of which Saline spray is the first listed.
NCT04228445 reports 1 study location spanning 1 distinct geographic area - top geographies include Nebraska.
Frequently Asked Questions
What is clinical trial NCT04228445 about?
NCT04228445 is a clinical study titled "3,3'-Dioxo-2,2'-Bisindolylidene-5,5'-Disulfonate Disodium 0.8% Solution as an Aid for Ureteral Patency". To determine whether the use of 3,3'-Dioxo-2,2'-Bisindolylidene-5,5'-Disulfonate Disodium 0.8% Solution for injection provides a visualization advantage compared to saline when used as an aid in the determination of ureteral patency
What is the current status of trial NCT04228445?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 121 participants. The study started on 2020-02-13. Estimated completion is 2021-06-03.
What conditions does trial NCT04228445 study?
This clinical trial studies the following conditions: Ureter Injury.
What interventions are being tested in trial NCT04228445?
The interventions under investigation include: Saline spray (DRUG), 3,3'-Dioxo-2,2'-bisindolylidene-5,5'-disulfonate disodium 0.8% (DRUG).
Who is sponsoring clinical trial NCT04228445?
This trial is sponsored by Prove pharm, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04228445 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ureter Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
IS-001 Injection in Patients Undergoing Robotic-Assisted Gynecological Surgery
COMPLETED · Phase 3
-
Evaluation of Lumitrace for Visualizing Ureters During Abdominopelvic Surgeries
RECRUITING · Phase 1
-
Indigotindisulfonate Sodium as an Aid in Determination of Ureteral Patency in Patient's With Renal Impairment
RECRUITING · Phase 4
-
Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency
RECRUITING · Phase 4
-
A Safety and Efficacy Study of IS-001 Injection in Patients Undergoing Robotic Hysterectomy
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.